Explore chapters and articles related to this topic
A clinical observational study on the efficacy of subcutaneous etonogestrel implants for adenomyosis in 20 patients
Published in Gynecological Endocrinology, 2021
Lekai Nie, Hongli Zou, Xiaotian Ma, Lei Cheng, Jun Jiao, Fenghua Wang, Weifeng Liang, Peihai Zhang
Implanon, a subcutaneous etonogestrel implant, was approved for use in China in 2012. The etonogestrel in Implanon prevents pregnancy primarily by suppressing ovulation [16]. At three years of use, the release rate of etonogestrel is 25–30 µg/day, producing serum etonogestrel levels of >90 pg/mL, which is the approximate ovulation inhibition level [17]. In addition, etonogestrel can also lead to cervical mucus thickening, affecting the growth of the endometrium and the movement of the ootid in the fallopian tube. The contraception rate was 100% in all patients in this study.